Anixa Biosciences Ownership 2024 | Who Owns Anixa Biosciences Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

11.83%

Insider Ownership

5.05%

Retail Ownership

83.12%

Institutional Holders

35.00

Anixa Biosciences Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC4.43%0.00%1,392,906--4,345,866Mar 31, 2024
LAIRD NORTON TRUST COMPANY, LLC1.92%0.26%604,235235,40063.82%1,885,213Mar 31, 2024
UBS GROUP AG1.71%0.00%536,307-44,271-7.63%1,673,278Mar 31, 2024
MISSION WEALTH MANAGEMENT, LP1.60%0.04%502,4201,2520.25%1,567,551Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.08%0.00%340,951340,951100.00%1,063,767Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%0.00%320,1487,6762.46%999,111Mar 31, 2024
LONG FOCUS CAPITAL MANAGEMENT, LLC0.53%0.03%165,701--516,987Mar 31, 2024
BLACKROCK INC.0.49%-154,662-2,135-1.36%482,546Mar 31, 2024
JANE STREET GROUP, LLC0.39%0.00%121,92478,541181.04%380,403Mar 31, 2024
BANK OF AMERICA CORP /DE/0.37%-116,914100,000591.23%364,772,000Mar 31, 2024
STATE STREET CORP0.34%-108,500--338,520Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.30%0.00%93,34344,89092.65%291,230Mar 31, 2024
BANK OF NEW YORK MELLON CORP0.28%0.00%87,050-9,604-9.94%271,597Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.22%0.00%68,80068,800100.00%215,000Mar 31, 2024
NORTHERN TRUST CORP0.20%-62,66211,16521.68%195,505Mar 31, 2024
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.0.13%0.00%41,0001,0002.50%128,000Mar 31, 2024
CITADEL ADVISORS LLC0.12%-38,25421,559129.13%119,352Mar 31, 2024
CI PRIVATE WEALTH, LLC0.12%0.00%37,400--116,688Mar 31, 2024
MORGAN STANLEY0.12%-37,1366631.82%115,864Mar 31, 2024
GEMMER ASSET MANAGEMENT LLC0.11%0.01%35,000--109,200Mar 31, 2024

Anixa Biosciences's largest institutional shareholder is VANGUARD GROUP INC, holding 4.43% of the company's total share outstanding, currently valued at $4.35M. The top 10 institutional shareholders own together 13.53% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LAIRD NORTON TRUST COMPANY, LLC1.92%0.26%604,235235,40063.82%1,885,213Mar 31, 2024
MISSION WEALTH MANAGEMENT, LP1.60%0.04%502,4201,2520.25%1,567,551Mar 31, 2024
TYLER-STONE WEALTH MANAGEMENT0.07%0.03%21,008--65,545Mar 31, 2024
LONG FOCUS CAPITAL MANAGEMENT, LLC0.53%0.03%165,701--516,987Mar 31, 2024
GEMMER ASSET MANAGEMENT LLC0.11%0.01%35,000--109,200Mar 31, 2024
WESTSIDE INVESTMENT MANAGEMENT, INC.0.04%0.01%13,900--43,368Mar 31, 2024
OCCUDO QUANTITATIVE STRATEGIES LP0.06%0.01%18,55418,554100.00%57,888Mar 31, 2024
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC0.04%0.00%14,000--46,900Mar 31, 2024
NATIONS FINANCIAL GROUP INC, /IA/ /ADV0.05%0.00%15,000--46,800Mar 31, 2024
STALEY CAPITAL ADVISERS INC0.03%0.00%10,00010,000100.00%31,200Mar 31, 2024
PARK CIRCLE CO0.00%0.00%500--1,560Mar 31, 2024
DAKOTA WEALTH MANAGEMENT0.05%0.00%15,000--46,800Mar 31, 2024
SIMPLICITY WEALTH,LLC0.04%0.00%13,96913,969100.00%43,583Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC0.04%0.00%11,1745,00080.98%34,863Mar 31, 2024
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.0.13%0.00%41,0001,0002.50%128,000Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.30%0.00%93,34344,89092.65%291,230Mar 31, 2024
UBS GROUP AG1.71%0.00%536,307-44,271-7.63%1,673,278Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%5,5352,832104.77%17,269Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.22%0.00%68,80068,800100.00%215,000Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC0.05%0.00%16,65516,655100.00%51,964Mar 31, 2024

The largest Anixa Biosciences shareholder by % of total assets is LAIRD NORTON TRUST COMPANY, LLC. The company owns 604.24K shares of Anixa Biosciences (ANIX), representing 0.26% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.08%0.00%340,951340,951100.00%1,063,767Mar 31, 2024
LAIRD NORTON TRUST COMPANY, LLC1.92%0.26%604,235235,40063.82%1,885,213Mar 31, 2024
BANK OF AMERICA CORP /DE/0.37%-116,914100,000591.23%364,772,000Mar 31, 2024
JANE STREET GROUP, LLC0.39%0.00%121,92478,541181.04%380,403Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.22%0.00%68,80068,800100.00%215,000Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.30%0.00%93,34344,89092.65%291,230Mar 31, 2024
CITADEL ADVISORS LLC0.12%-38,25421,559129.13%119,352Mar 31, 2024
GOLDMAN SACHS GROUP INC0.07%-20,50120,501100.00%63,963Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.06%-20,20020,200100.00%63,024Mar 31, 2024
OCCUDO QUANTITATIVE STRATEGIES LP0.06%0.01%18,55418,554100.00%57,888Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC0.05%0.00%16,65516,655100.00%51,964Mar 31, 2024
SQUAREPOINT OPS LLC0.05%0.00%15,89715,897100.00%49,599Mar 31, 2024
MARSHALL WACE, LLP0.08%0.00%26,37215,697147.04%82,280Mar 31, 2024
SIMPLICITY WEALTH,LLC0.04%0.00%13,96913,969100.00%43,583Mar 31, 2024
NORTHERN TRUST CORP0.20%-62,66211,16521.68%195,505Mar 31, 2024
STALEY CAPITAL ADVISERS INC0.03%0.00%10,00010,000100.00%31,200Mar 31, 2024
SIMPLEX TRADING, LLC0.03%-9,0518,7582989.08%28,000Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%0.00%320,1487,6762.46%999,111Mar 31, 2024
CITADEL ADVISORS LLC0.05%-14,5005,60062.92%45,240Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC0.04%0.00%11,1745,00080.98%34,863Mar 31, 2024

As of Mar 31 2024, Anixa Biosciences's largest institutional buyer is SUSQUEHANNA INTERNATIONAL GROUP, LLP. The company purchased 340.95K stocks of ANIX, valued at $1.06M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG1.71%0.00%536,307-44,271-7.63%1,673,278Mar 31, 2024
RAYMOND JAMES & ASSOCIATES0.06%-17,755-37,894-68.09%55,396Mar 31, 2024
CITADEL ADVISORS LLC0.01%-4,100-16,600-80.19%12,792Mar 31, 2024
CONCORDE ASSET MANAGEMENT, LLC----15,459-100.00%-Mar 31, 2024
Y-INTERCEPT (HONG KONG) LTD----14,372-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP0.28%0.00%87,050-9,604-9.94%271,597Mar 31, 2024
JPMORGAN CHASE & CO----6,857-100.00%-Mar 31, 2024
TRADITION WEALTH MANAGEMENT, LLC----5,600-100.00%-Mar 31, 2024
BLACKROCK INC.0.49%-154,662-2,135-1.36%482,546Mar 31, 2024
LPL FINANCIAL LLC0.08%-26,692-1,450-5.15%83,279Mar 31, 2024
GROUP ONE TRADING, L.P.----1,285-100.00%-Mar 31, 2024
ROYAL BANK OF CANADA0.00%-1,000-153-13.27%3,000Mar 31, 2024
LARSON FINANCIAL GROUP LLC0.00%0.00%500-25-4.76%1,560,000Mar 31, 2024
TYLER-STONE WEALTH MANAGEMENT0.07%0.03%21,008--65,545Mar 31, 2024
LONG FOCUS CAPITAL MANAGEMENT, LLC0.53%0.03%165,701--516,987Mar 31, 2024
GEMMER ASSET MANAGEMENT LLC0.11%0.01%35,000--109,200Mar 31, 2024
WESTSIDE INVESTMENT MANAGEMENT, INC.0.04%0.01%13,900--43,368Mar 31, 2024
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC0.04%0.00%14,000--46,900Mar 31, 2024
NATIONS FINANCIAL GROUP INC, /IA/ /ADV0.05%0.00%15,000--46,800Mar 31, 2024
PARK CIRCLE CO0.00%0.00%500--1,560Mar 31, 2024

As of Mar 31 2024, Anixa Biosciences's biggest institutional seller is UBS GROUP AG. The company sold -44.27K shares of ANIX, valued at $1.67M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.08%0.00%340,951340,951100.00%1,063,767Mar 31, 2024
GOLDMAN SACHS GROUP INC0.07%-20,50120,501100.00%63,963Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.06%-20,20020,200100.00%63,024Mar 31, 2024
OCCUDO QUANTITATIVE STRATEGIES LP0.06%0.01%18,55418,554100.00%57,888Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC0.05%0.00%16,65516,655100.00%51,964Mar 31, 2024
SIMPLICITY WEALTH,LLC0.04%0.00%13,96913,969100.00%43,583Mar 31, 2024
STALEY CAPITAL ADVISERS INC0.03%0.00%10,00010,000100.00%31,200Mar 31, 2024
LAZARD ASSET MANAGEMENT LLC0.00%-1,1941,194100.00%3,000Mar 31, 2024
FMR LLC0.00%-250250100.00%780Mar 31, 2024

Anixa Biosciences's largest new institutional shareholder by number of shares is SUSQUEHANNA INTERNATIONAL GROUP, LLP, purchased 340.95K shares, valued at $1.06M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CONCORDE ASSET MANAGEMENT, LLC----15,459-100.00%-Mar 31, 2024
Y-INTERCEPT (HONG KONG) LTD----14,372-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----6,857-100.00%-Mar 31, 2024
TRADITION WEALTH MANAGEMENT, LLC----5,600-100.00%-Mar 31, 2024
GROUP ONE TRADING, L.P.----1,285-100.00%-Mar 31, 2024

Anixa Biosciences's largest sold out institutional shareholder by shares sold is CONCORDE ASSET MANAGEMENT, LLC, sold -15.46K shares, valued at -, as of undefined.

Anixa Biosciences Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.03%12,599--Dec 31, 2023
BRIDGEWAY FUNDS INC0.01%21,000--Dec 29, 2023
VANGUARD INDEX FUNDS0.00%1,769,157450,64234.18%Dec 31, 2023
AdvisorShares Trust0.00%8,093--Dec 29, 2023
FIDELITY CONCORD STREET TRUST0.00%289,68813,9805.07%Feb 29, 2024
ETF Managers Trust0.00%7,644--Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%21,079--Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%14,225--Jan 31, 2024
WILSHIRE MUTUAL FUNDS INC0.00%3,590--Dec 31, 2023
Dimensional ETF Trust0.00%4,426--Jan 31, 2024
EQ ADVISORS TRUST0.00%5,059--Dec 31, 2023
iSHARES TRUST0.00%65,668--Feb 29, 2024
NORTHERN FUNDS0.00%3,525--Dec 29, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%386--Dec 31, 2023

Anixa Biosciences's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 12.60K shares, compromising 0.03% of its total assets.

Anixa Biosciences Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2435-36.36%
31 Dec, 235510.00%
30 Sep, 235011.11%
30 Jun, 2345-
31 Mar, 2345-10.00%
31 Dec, 225025.00%
30 Sep, 2240-9.09%
30 Jun, 224410.00%
31 Mar, 2240-4.76%
31 Dec, 214216.67%
30 Sep, 213616.13%
30 Jun, 213114.81%
31 Mar, 212735.00%
31 Dec, 2020-
30 Sep, 202011.11%
30 Jun, 201820.00%
31 Mar, 2015-
31 Dec, 1915-
30 Sep, 19157.14%
30 Jun, 1914-
31 Mar, 19147.69%
31 Dec, 1813-

As of 31 Mar 24, 35 institutions are holding Anixa Biosciences's shares, representing a decrease of -36.36% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 243,720,874-14.22%
31 Dec, 234,337,49211.45%
30 Sep, 233,891,7108.42%
30 Jun, 233,589,5992.30%
31 Mar, 233,508,872-1.58%
31 Dec, 223,565,1793.79%
30 Sep, 223,434,8585.67%
30 Jun, 223,250,681-1.63%
31 Mar, 223,304,604-3.34%
31 Dec, 213,418,6879.17%
30 Sep, 213,131,6006.70%
30 Jun, 212,934,89216.82%
31 Mar, 212,512,22639.53%
31 Dec, 201,800,474-1.45%
30 Sep, 201,826,96114.37%
30 Jun, 201,597,36615.47%
31 Mar, 201,383,3193.86%
31 Dec, 191,331,8881.45%
30 Sep, 191,312,8717.03%
30 Jun, 191,226,634-1.98%
31 Mar, 191,251,43614.19%
31 Dec, 181,095,942-

Anixa Biosciences (ANIX) has 3.72M shares outstanding as of 31 Mar 24, down -14.22% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2411.83%6.04%
31 Dec, 2314.00%8.87%
30 Sep, 2312.56%9.33%
30 Jun, 2311.61%9.01%
31 Mar, 2311.35%8.54%
31 Dec, 2211.53%9.02%
30 Sep, 2211.31%9.92%
30 Jun, 2210.68%8.89%
31 Mar, 2210.96%8.51%
31 Dec, 2111.35%9.45%
30 Sep, 2110.96%11.80%
30 Jun, 219.64%12.55%
31 Mar, 218.76%17.12%
31 Dec, 207.15%13.57%
30 Sep, 207.26%15.27%
30 Jun, 206.90%16.13%
31 Mar, 206.54%15.80%
31 Dec, 196.43%16.00%
30 Sep, 196.34%17.03%
30 Jun, 196.10%15.04%
31 Mar, 196.37%19.49%
31 Dec, 185.72%-

As of 31 Mar 24, Anixa Biosciences is held by 11.83% institutional shareholders, representing a 6.04% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 2414-30.00%
31 Dec, 232053.85%
30 Sep, 2313-13.33%
30 Jun, 231525.00%
31 Mar, 2312-36.84%
31 Dec, 221935.71%
30 Sep, 2214-17.65%
30 Jun, 2217-5.56%
31 Mar, 2218-5.26%
31 Dec, 211926.67%
30 Sep, 2115-6.25%
30 Jun, 2116-15.79%
31 Mar, 211946.15%
31 Dec, 201330.00%
30 Sep, 2010-9.09%
30 Jun, 201183.33%
31 Mar, 206-14.29%
31 Dec, 197-12.50%
30 Sep, 19814.29%
30 Jun, 197-12.50%
31 Mar, 198-38.46%
31 Dec, 1813-

14 institutional shareholders have increased their position in ANIX stock as of 31 Mar 24 compared to 20 in the previous quarter (a -30.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 246-50.00%
31 Dec, 2312-14.29%
30 Sep, 2314100.00%
30 Jun, 237-12.50%
31 Mar, 238-38.46%
31 Dec, 221385.71%
30 Sep, 227-36.36%
30 Jun, 221110.00%
31 Mar, 221011.11%
31 Dec, 219-10.00%
30 Sep, 2110100.00%
30 Jun, 215-16.67%
31 Mar, 21620.00%
31 Dec, 205-
30 Sep, 20525.00%
30 Jun, 204-
31 Mar, 204-20.00%
31 Dec, 195150.00%
30 Sep, 192-33.33%
30 Jun, 193-25.00%
31 Mar, 194-
31 Dec, 18--

6 institutional shareholders have reduced their position in ANIX stock as of 31 Mar 24 compared to 12 in the previous quarter (a -50.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2435-36.36%3,720,874-14.22%11.83%6.04%14-30.00%6-50.00%
31 Dec, 235510.00%4,337,49211.45%14.00%8.87%2053.85%12-14.29%
30 Sep, 235011.11%3,891,7108.42%12.56%9.33%13-13.33%14100.00%
30 Jun, 2345-3,589,5992.30%11.61%9.01%1525.00%7-12.50%
31 Mar, 2345-10.00%3,508,872-1.58%11.35%8.54%12-36.84%8-38.46%
31 Dec, 225025.00%3,565,1793.79%11.53%9.02%1935.71%1385.71%
30 Sep, 2240-9.09%3,434,8585.67%11.31%9.92%14-17.65%7-36.36%
30 Jun, 224410.00%3,250,681-1.63%10.68%8.89%17-5.56%1110.00%
31 Mar, 2240-4.76%3,304,604-3.34%10.96%8.51%18-5.26%1011.11%
31 Dec, 214216.67%3,418,6879.17%11.35%9.45%1926.67%9-10.00%
30 Sep, 213616.13%3,131,6006.70%10.96%11.80%15-6.25%10100.00%
30 Jun, 213114.81%2,934,89216.82%9.64%12.55%16-15.79%5-16.67%
31 Mar, 212735.00%2,512,22639.53%8.76%17.12%1946.15%620.00%
31 Dec, 2020-1,800,474-1.45%7.15%13.57%1330.00%5-
30 Sep, 202011.11%1,826,96114.37%7.26%15.27%10-9.09%525.00%
30 Jun, 201820.00%1,597,36615.47%6.90%16.13%1183.33%4-
31 Mar, 2015-1,383,3193.86%6.54%15.80%6-14.29%4-20.00%
31 Dec, 1915-1,331,8881.45%6.43%16.00%7-12.50%5150.00%
30 Sep, 19157.14%1,312,8717.03%6.34%17.03%814.29%2-33.33%
30 Jun, 1914-1,226,634-1.98%6.10%15.04%7-12.50%3-25.00%
31 Mar, 19147.69%1,251,43614.19%6.37%19.49%8-38.46%4-
31 Dec, 1813-1,095,942-5.72%-13---

Anixa Biosciences Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 10, 2024Titterton Lewis H jrdirector-P-PurchaseBuy15,009$3.28$49.23K838,037
Mar 15, 2024Baskies Arnold Mdirector-P-PurchaseBuy10,000$3.63$36.30K110,000
Mar 15, 2024KUMAR AMITofficer Chief Executive OfficerP-PurchaseBuy30,000$3.22$96.60K491,925
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerS-SaleSell11,800$3.57$42.13K461,925
Jul 21, 2023Catelani Michaelofficer President, COO & CFOP-PurchaseBuy5,500$3.64$20.02K26,655

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 10, 2024Titterton Lewis H jrdirector-P-PurchaseBuy15,009$3.28$49.23K838,037
Mar 15, 2024Baskies Arnold Mdirector-P-PurchaseBuy10,000$3.63$36.30K110,000
Mar 15, 2024KUMAR AMITofficer Chief Executive OfficerP-PurchaseBuy30,000$3.22$96.60K491,925
Jul 21, 2023Catelani Michaelofficer President, COO & CFOP-PurchaseBuy5,500$3.64$20.02K26,655

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Oct 11, 2023Titterton Lewis H jrdirector-M-ExemptSell16,000$2.58$41.20K-
Jul 31, 2023Titterton Lewis H jrdirector-F-InKindSell87,042$3.55$309.00K807,028
Jul 31, 2023Titterton Lewis H jrdirector-M-ExemptSell120,000$2.58$309.00K-
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerF-InKindSell28,375$3.63$103.00K473,725
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerS-SaleSell11,800$3.57$42.13K461,925
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerM-ExemptSell40,000$2.58$103.00K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 02, 2024Catelani Michaelofficer President, COO, & CFOA-AwardBuy1,189$2.52$3.00K28,961
Apr 10, 2024Titterton Lewis H jrdirector-P-PurchaseBuy15,009$3.28$49.23K838,037
Mar 15, 2024Baskies Arnold Mdirector-P-PurchaseBuy10,000$3.63$36.30K110,000
Mar 15, 2024KUMAR AMITofficer Chief Executive OfficerP-PurchaseBuy30,000$3.22$96.60K491,925
Jan 16, 2024Baskies Arnold Mdirector-A-AwardBuy25,000$4.39$109.75K25,000
Jan 16, 2024Gottschalk Emilydirector-A-AwardBuy25,000$4.39$109.75K25,000
Jan 16, 2024Catelani Michaelofficer President, COO & CFOA-AwardBuy350,000$4.39$1.54M350,000
Jan 16, 2024KUMAR AMITdirector, officer Chief Executive OfficerA-AwardBuy700,000$4.39$3.07M700,000
Jan 16, 2024Titterton Lewis H jrdirector-A-AwardBuy25,000$4.39$109.75K25,000
Nov 02, 2023Catelani Michaelofficer President, COO & CFOA-AwardBuy1,117$2.69$3.00K27,772
Oct 11, 2023Titterton Lewis H jrdirector-M-ExemptBuy16,000$2.58$41.20K823,028
Oct 11, 2023Titterton Lewis H jrdirector-M-ExemptSell16,000$2.58$41.20K-
Jul 31, 2023Titterton Lewis H jrdirector-M-ExemptBuy120,000$2.58$309.00K894,070
Jul 31, 2023Titterton Lewis H jrdirector-F-InKindSell87,042$3.55$309.00K807,028
Jul 31, 2023Titterton Lewis H jrdirector-M-ExemptSell120,000$2.58$309.00K-
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerM-ExemptBuy40,000$2.58$103.00K502,100
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerF-InKindSell28,375$3.63$103.00K473,725
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerS-SaleSell11,800$3.57$42.13K461,925
Jul 31, 2023KUMAR AMITdirector, officer Chief Executive OfficerM-ExemptSell40,000$2.58$103.00K-
Jul 21, 2023Catelani Michaelofficer President, COO & CFOP-PurchaseBuy5,500$3.64$20.02K26,655

The last insider sell of Anixa Biosciences's stock was made by Titterton Lewis H jr on Oct 11 2023, selling 16,000 shares at $2.58 per share (valued at $41.20K). The last insider buy of ANIX was made by Titterton Lewis H jr on Apr 10 2024, buying 15,009 shares at $3.28 per share (worth $49.23K).

Anixa Biosciences Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20242--
Q1 20247--
Q4 202321200.00%
Q3 20233560.00%
Q2 20231--
Q1 202310--
Q4 20221--
Q3 20222450.00%
Q2 202281800.00%
Q1 202215--
Q4 20213--
Q3 20219--
Q2 20211111100.00%
Q1 202151500.00%
Q4 20203--
Q3 20207--
Q2 20204--
Q1 20208--
Q4 201981800.00%
Q3 2019195380.00%

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Anixa Biosciences's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20241--
Q1 20242--
Q4 2023---
Q3 202311100.00%
Q2 2023---
Q1 2023---
Q4 2022---
Q3 2022---
Q2 20223--
Q1 20225--
Q4 20212--
Q3 20219--
Q2 20213--
Q1 20215--
Q4 2020---
Q3 20202--
Q2 20203--
Q1 20208--
Q4 2019---
Q3 20192--

As of Q2 2024, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Anixa Biosciences's stocks.

Anixa Biosciences Peer Ownership


TickerCompany
ANTXAN2 Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
RZLTRezolute, Inc.
PMVPPMV Pharmaceuticals, Inc.
TFFPTFF Pharmaceuticals, Inc.
PYPDPolyPid Ltd.
INABIN8bio, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
CUECue Biopharma, Inc.
ACLXArcellx, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
ANVSAnnovis Bio, Inc.
INMBINmune Bio, Inc.
IMNMImmunome, Inc.

ANIX Ownership FAQ


Anixa Biosciences is owned by institutional shareholders (11.83%), insiders (5.05%), and public (83.12%). The largest institutional shareholder of Anixa Biosciences is VANGUARD GROUP INC (4.43% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).

Anixa Biosciences's major institutional shareholders are VANGUARD GROUP INC, LAIRD NORTON TRUST COMPANY, LLC, UBS GROUP AG, MISSION WEALTH MANAGEMENT, LP, and SUSQUEHANNA INTERNATIONAL GROUP, LLP. The top five shareholders own together 10.74% of the company's share outstanding.

As of Mar 2024, there are 35 institutional shareholders of Anixa Biosciences.

VANGUARD GROUP INC owns 1.39M shares of Anixa Biosciences, representing 4.43% of the company's total shares outstanding, valued at $4.35M (as of Mar 2024).

As of Mar 2024, LAIRD NORTON TRUST COMPANY, LLC holds 604.24K shares of Anixa Biosciences (ANIX), compromising 1.92% of the company, valued at $1.89M.

UBS GROUP AG is the third largest holder of Anixa Biosciences. The company owns 536.31K of the company's shares outstanding (worth $1.67M).